Results 141 to 150 of about 130,251 (209)

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group. [PDF]

Cancer Discov
Stieglitz E, Lee AG, Angus SP, Davis C, Barkauskas DA, Hall D, Kogan SC, Meyer J, Rhodes SD, Tasian SK, Xuei X, Shannon K, Loh ML, Fox E, Weigel BJ.   +14 more
europepmc   +1 more source

MEK 1/2 Inhibitor AS703988/MSC2015103B [PDF]

, 2020
openaire   +1 more source

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib: A Nonrandomized Clinical Trial.

JAMA Dermatol
Gross AM, Reid OH, Baldwin LA, Cannon A, Choo-Wosoba H, Steinberg SM, Lobbous M, Wolters PL, Pichard DC, Tibery CM, Dombi E, Derdak J, Widemann BC, Korf BR.   +13 more
europepmc   +1 more source

Combination of AURKA inhibitor and MEK inhibitor strongly enhances G1 arrest and induces synergistic antitumor effect on <i>KRAS</i> or <i>BRAF</i> mutant colon cancer cells. [PDF]

Biochem Biophys Rep
Sato M, Yamamoto Y, Moriwaki T, Fukuda K, Tsuchiya K.   +4 more
europepmc   +1 more source

The clinically relevant MEK inhibitor mirdametinib combined with D-cycloserine and prediction error disrupts fear memory in PTSD models. [PDF]

Transl Psychiatry
Raut SB, Joly F, Haass NK, Eri R, Canales JJ, Benedek DM, Ursano RJ, Johnson LR.   +7 more
europepmc   +1 more source

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer. [PDF]

Breast Cancer Res Treat
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B.   +23 more
europepmc   +1 more source

MEK inhibitor PD0325901 upregulates CD34 expression in endothelial cells via inhibition of ERK phosphorylation. [PDF]

Regen Ther
Hosoda C, Mitani S, Sakata A, Kasuda S, Onodera Y, Takabayashi Y, Shima M, Tatsumi K.   +7 more
europepmc   +1 more source

Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation. [PDF]

Oncologist
Jeng-Miller KW, Miller MA, Heier JS.
europepmc   +1 more source

Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1. [PDF]

Sci Adv
Sarin KY, Bradshaw M, O'Mara C, Shahryari J, Kincaid J, Kempers S, Tu JH, Dhawan S, DuBois J, Wilson D, Horwath P, de Souza MP, Powala C, Kochendoerfer GG, Plotkin SR, Webster GF, Le LQ.   +16 more
europepmc   +1 more source

MEK-inhibitor treatment reduces the induction of regulatory T cells in mice after influenza A virus infection. [PDF]

Front Immunol
Koch-Heier J, Vogel AB, Füll Y, Ebensperger M, Schönsiegel A, Zinser RS, Planz O.   +6 more
europepmc   +1 more source